Omar Yaxmehen Bello-Chavolla
Research Subjects
Research Interests
Omar Yaxmehen Bello-Chavolla has a total of 461 co-authors. Here are the top co-authors by number of shared publications:
- Neftali Eduardo Antonio-Villa
Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez , Mexico City
52 shared publications - Arsenio Vargas-Vázquez
Facultad de Medicina, Universidad Nacional Autónoma de México
43 shared publications - Carlos Alberto Fermín-Martínez
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico
37 shared publications - Carlos Alberto Aguilar Salinas
Dirección de Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Ciudad de México, México...
26 shared publications - Luisa Fernández-Chirino
Research Division, Instituto Nacional de Geriatría
22 shared publications - Daniel Ramírez-García
Research Division, Instituto Nacional de Geriatría
21 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 40, 49-61
Therapeutic landscape for diabetic macular edema: durable strategies with a focus on aflibercept 8 mg
To evaluate current therapies for diabetic macular edema (DME), with emphasis on durability, safety, access, and the evidence supporting aflibercept 8 mg. An expert-selected narrative synthesis of primary clinical trials, pharmacologic studies, regulatory documents, and selected real-world evidence published from January 1, 2000, through August 8, 2026, was performed. Anti-vascular endothelial growth factor therapy remains first-line treatment for most center-involved DME with visual impairment, but observation or focal/grid laser is reasonable for selected eyes with good visual acuity. In PHOTON, aflibercept 8 mg every 12 or 16 weeks after three monthly doses was noninferior to aflibercept 2 mg every 8 weeks for visual acuity at week 48; durability and similar safety were maintained through week 96 with fewer injections. Faricimab, brolucizumab, dexamethasone and fluocinolone implants, and the ranibizumab Port Delivery System offer alternative durability profiles with distinct evidence and risks. Aflibercept 8 mg provides an effective option for extending treatment intervals while maintaining visual and anatomical outcomes; however, no single therapeutic strategy is optimal for all patients. Treatment should therefore be individualized according to visual and anatomical response, ocular and systemic characteristics, patient preference, treatment burden, access, and local health-system constraints.
- 3 September 2026
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 40, 49-61
Open AccessTherapeutic landscape for diabetic macular edema: durable strategies with a focus on aflibercept 8 mg
To evaluate current therapies for diabetic macular edema (DME), with emphasis on durability, safety, access, and the evidence supporting aflibercept 8 mg. An expert-selected narrative synthesis of primary clinical trials, pharmacologic studies, regulatory documents, and selected real-world evidence published from January 1, 2000, through August 8, 2026, was performed. Anti-vascular endothelial growth factor therapy remains first-line treatment for most center-involved DME with visual impairment, but observation or focal/grid laser is reasonable for selected eyes with good visual acuity. In PHOTON, aflibercept 8 mg every 12 or 16 weeks after three monthly doses was noninferior to aflibercept 2 mg every 8 weeks for visual acuity at week 48; durability and similar safety were maintained through week 96 with fewer injections. Faricimab, brolucizumab, dexamethasone and fluocinolone implants, and the ranibizumab Port Delivery System offer alternative durability profiles with distinct evidence and risks. Aflibercept 8 mg provides an effective option for extending treatment intervals while maintaining visual and anatomical outcomes; however, no single therapeutic strategy is optimal for all patients. Treatment should therefore be individualized according to visual and anatomical response, ocular and systemic characteristics, patient preference, treatment burden, access, and local health-system constraints.
- 17 July 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (7) , 103491
Association between Physical Activity and Accelerated Aging Using S-Anthropoage: A Secondary Analysis of the Mexican Health and Aging Study
- 17 July 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (7) , 103491
Association between Physical Activity and Accelerated Aging Using S-Anthropoage: A Secondary Analysis of the Mexican Health and Aging Study
- Open Access
- 17 July 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 62, 101576
Data-driven subclassification of type 2 diabetes in Mexico: a conceptual framework to improve diabetes care
- 17 July 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 62, 101576
Open AccessData-driven subclassification of type 2 diabetes in Mexico: a conceptual framework to improve diabetes care
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Evolving Patterns of Prevalence and Management of Hypertension Phenotypes in Mexico: A 2-Decade Analysis of Nationally Representative Surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension phenotypes in the Mexican population over 2 decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000–2024), including 146 904 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure ≥140/90 mm Hg; undiagnosed hypertension (UDH) as blood pressure ≥140/90 mm Hg without prior diagnosis; and untreated hypertension as a prior diagnosis without treatment. UDH was classified as isolated systolic, isolated diastolic, or systolic-diastolic hypertension. We assessed trends with Poisson models and determinants of UDH and untreated hypertension with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 33.1% in 2000 to 26.0% in 2024, concurrently with increases in diagnosed (12.3%–19.3%) and decreases in undiagnosed (20.7%–6.7%) hypertension. Isolated diastolic hypertension and systolic-diastolic hypertension declined over time, while isolated systolic hypertension increased, particularly among older adults. Among diagnosed cases, treatment percentage increased (69%–80%) and blood pressure control improved (40.5%–81.1%). Despite these trends, by 2024, ≈5 million Mexican adults still had UDH (25.9% of all hypertension cases), 2.9 million remained untreated, and 2.7 million were uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and those with social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and untreated hypertension. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Evolving Patterns of Prevalence and Management of Hypertension Phenotypes in Mexico: A 2-Decade Analysis of Nationally Representative Surveys
BACKGROUND: Systemic arterial hypertension is a public health concern, and timely diagnosis and management are critical to mitigate long-term effects. Here, we evaluated prevalence trends and determinants of hypertension phenotypes in the Mexican population over 2 decades. METHODS: We analyzed cross-sectional Mexican Health and Nutrition Surveys (2000–2024), including 146 904 adults aged ≥20 years. Hypertension was defined as self-reported diagnosis or blood pressure ≥140/90 mm Hg; undiagnosed hypertension (UDH) as blood pressure ≥140/90 mm Hg without prior diagnosis; and untreated hypertension as a prior diagnosis without treatment. UDH was classified as isolated systolic, isolated diastolic, or systolic-diastolic hypertension. We assessed trends with Poisson models and determinants of UDH and untreated hypertension with logistic models. RESULTS: We observed an overall decrease in hypertension prevalence from 33.1% in 2000 to 26.0% in 2024, concurrently with increases in diagnosed (12.3%–19.3%) and decreases in undiagnosed (20.7%–6.7%) hypertension. Isolated diastolic hypertension and systolic-diastolic hypertension declined over time, while isolated systolic hypertension increased, particularly among older adults. Among diagnosed cases, treatment percentage increased (69%–80%) and blood pressure control improved (40.5%–81.1%). Despite these trends, by 2024, ≈5 million Mexican adults still had UDH (25.9% of all hypertension cases), 2.9 million remained untreated, and 2.7 million were uncontrolled. Lack of diagnosis and treatment were more likely among men, individuals with unhealthy lifestyles, and those with social disadvantage. CONCLUSIONS: Results highlight evolving trends in hypertension diagnosis, treatment, and control in Mexico, with persistent challenges in UDH and untreated hypertension. Strengthening screening, treatment access, and equity is crucial to reduce hypertension-related cardiovascular risk.
- 20 May 2026
- Published by BMJ in Considerations in Medicine
- Vol. 4 (1) , e000059
Science is more than just breakthroughs: why clinical research needs Considerations in Medicine
- 20 May 2026
- Published by BMJ in Considerations in Medicine
- Vol. 4 (1) , e000059
Science is more than just breakthroughs: why clinical research needs Considerations in Medicine
- 29 April 2026
- Published by Wiley in Gerodontology
A Mediation Analysis of Oral Health, Anthropometric Characteristics and Frailty Among Community‐Dwelling Mexican Older Adults
Introduction: Frailty has been associated with oral health, a broad and heterogeneous construct. Due to its complexity and multi‐dimensional nature, clarifying the role of oral health in the development of frailty remains challenging; potential mediating factors are being examined to improve its comprehension. This study aims to examine the relationship between frailty and oral deficits, considering biological age as a potential mediator using samples of Mexicans aged over 60. Methods: This study is a secondary analysis of the Cohort of Obesity, Sarcopenia and Frailty of Older Mexican Adults (COSFOMA), a cohort of Mexican older adults starting at age 60. We analysed pre‐pandemic data from 2019, including questionnaires, anthropometric measures, oral health evaluations and physical performance tests. Frailty was assessed using a standard Frailty Index, constructed from health‐related deficits. Oral health was evaluated with the New Oral Health Index and the Geriatric Oral Health Assessment Index (GOHAI). Accelerated aging was estimated using AnthropoAge. Associations between frailty, oral health and biological aging were examined using generalised linear models (GLMs) with bootstrapped standard errors. Results: The analytical sample comprised 1657 participants. We found that women had higher scores in BMI categories, use of prostheses, while men had higher scores of dental biofilm, gingivitis, caries and number of missing teeth. Values were higher among those with oral health deficits. A sex‐stratified sub‐analysis was performed; among men, no statistically significant average causal mediation effect (ACME) was found. However, among women, the direct effect of oral health deficits on frailty was not statistically significant, indicating associational evidence about mediation by accelerated aging. The proportion was 51.86%. Discussion: Oral health deficits were associated with frailty, evidence consistent with an indirect pathway through accelerated aging. Among women, this indirect association was primarily observed in aging profiles characterised by disproportionate fat distribution and reduced lean mass. These findings highlight potential pathways linking oral health and frailty that warrant further investigation.
- 29 April 2026
- Published by Wiley in Gerodontology
A Mediation Analysis of Oral Health, Anthropometric Characteristics and Frailty Among Community‐Dwelling Mexican Older Adults
Introduction: Frailty has been associated with oral health, a broad and heterogeneous construct. Due to its complexity and multi‐dimensional nature, clarifying the role of oral health in the development of frailty remains challenging; potential mediating factors are being examined to improve its comprehension. This study aims to examine the relationship between frailty and oral deficits, considering biological age as a potential mediator using samples of Mexicans aged over 60. Methods: This study is a secondary analysis of the Cohort of Obesity, Sarcopenia and Frailty of Older Mexican Adults (COSFOMA), a cohort of Mexican older adults starting at age 60. We analysed pre‐pandemic data from 2019, including questionnaires, anthropometric measures, oral health evaluations and physical performance tests. Frailty was assessed using a standard Frailty Index, constructed from health‐related deficits. Oral health was evaluated with the New Oral Health Index and the Geriatric Oral Health Assessment Index (GOHAI). Accelerated aging was estimated using AnthropoAge. Associations between frailty, oral health and biological aging were examined using generalised linear models (GLMs) with bootstrapped standard errors. Results: The analytical sample comprised 1657 participants. We found that women had higher scores in BMI categories, use of prostheses, while men had higher scores of dental biofilm, gingivitis, caries and number of missing teeth. Values were higher among those with oral health deficits. A sex‐stratified sub‐analysis was performed; among men, no statistically significant average causal mediation effect (ACME) was found. However, among women, the direct effect of oral health deficits on frailty was not statistically significant, indicating associational evidence about mediation by accelerated aging. The proportion was 51.86%. Discussion: Oral health deficits were associated with frailty, evidence consistent with an indirect pathway through accelerated aging. Among women, this indirect association was primarily observed in aging profiles characterised by disproportionate fat distribution and reduced lean mass. These findings highlight potential pathways linking oral health and frailty that warrant further investigation.
- Open Access
Prediabetes and glycemic transitions as determinants of frailty and functional decline in adults aged 50 years and older: A longitudinal analysis from five multinational aging cohorts
Background: Prediabetes is highly prevalent in older adults and is characterized by heterogeneous clinical trajectories, including regression to normoglycemia and progression to diabetes. While prediabetes has been associated with impaired physical function and frailty, the longitudinal impact of both a single diagnosis and dynamic glycemic transitions on functional outcomes remains unclear. We aimed to evaluate associations between baseline prediabetes and glycemic transitions over time with trajectories of functional capacity and frailty in older adults. Methods: We conducted a pooled analysis of harmonized data from five nationally representative longitudinal aging cohorts (MHAS, HRS, CHARLS, ELSA, CRELES) within the Gateway to Global Aging Data, including adults aged ≥50 years with ≥1 HbA1c measurements. Prediabetes was defined per ADA criteria (HbA1c 5.7-6.4%). Functional outcomes included activities of daily living (ADL), instrumental ADL (IADL), and frailty assessed using Fried phenotype, FRAIL scale, and a deficit-accumulation Frailty Index (FI). Mixed-effects Poisson models estimated incidence rate ratios (IRRs) for baseline prediabetes, while generalized estimating equations assessed time-varying glycemic status and transition trajectories. Models were adjusted for age, sex, cohort, and time-varying covariates, with sensitivity analyses including BMI, smoking, and alcohol intake. Findings: Among 18,571 participants (median follow-up 13.6 years), baseline prediabetes was associated with increased progression of functional deficits and frailty compared with normoglycemia, including higher FI values and accelerated FI progression. Prediabetes was associated with higher incidence of ADL, IADL, and multimorbidity deficits from early follow-up, although time-dependent changes in incidence rates were not significant. In time-varying analyses (n=7,840), both prediabetes and diabetes were associated with higher incidence of functional deficits compared with normoglycemia, with diabetes showing the strongest effects across all outcomes. Diabetes was associated with greater FI burden and accelerated progression, whereas prediabetes showed a smaller increase, with attenuation over time. Among individuals with baseline prediabetes, regression to normoglycemia occurred in 20.8% and was associated with increased incidence of ADL and frailty deficits. In contrast, progression to diabetes occurred in 24.3%, and was associated with lower risk of incident ADL and Fried frailty deficits compared to stable prediabetes. Interpretation: Prediabetes is associated with increased risk of functional decline, frailty, and deficit accumulation in older adults, independent of progression to diabetes. Regression to normoglycemia was associated with higher risk of functional deterioration. These findings suggest that prediabetes reflects a state of metabolic vulnerability linked to biological aging rather than solely a precursor to diabetes and highlights a need to reframe its clinical significance in older populations. Funding: This research was supported by Instituto Nacional de Geriatría in Mexico. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed up to April 1, 2026, using the terms (“prediabetes”) AND (“frailty” OR “functional decline” OR “activities of daily living” OR “mortality”) AND (“older adults” OR “aging” OR “longitudinal” OR “cohort”). Existing evidence from predominantly single-country and cross-sectional studies suggests that prediabetes is associated with increased risk of frailty, disability, and adverse health outcomes in older adults. However, findings have been inconsistent, particularly regarding incident versus prevalent outcomes and the role of competing risks in aging populations. Importantly, few studies have used harmonized multinational longitudinal data, incorporated repeated measures of glycemic status, or evaluated multiple complementary frailty constructs. The impact of dynamic glycemic transitions, including regression to normoglycemia and progression to diabetes, on functional trajectories remains poorly understood. Added value of this study: This study leverages harmonized longitudinal data from five nationally representative aging cohorts from Mexico, England, China, Costa Rica and the United States to examine both baseline prediabetes and time-varying glycemic status in relation to trajectories of functional decline and frailty. By integrating multiple validated measures of functional capacity and frailty, and applying longitudinal modeling strategies, we provide a comprehensive assessment of the relationship between prediabetes and age-related outcomes. We further characterize glycemic transition trajectories and show that regression to normoglycemia among older adults with prediabetes is associated with increased risk of frailty, while progression to diabetes does not uniformly confer additional risk beyond stable prediabetes. Implications of all the available evidence: Our results support a reconceptualization of prediabetes in older adults as a marker of systemic vulnerability rather than solely a precursor to diabetes. Glycemic status in later life appears to also reflect underlying physiological reserve, with dynamic changes potentially signaling deterioration rather than improvement. Our findings suggest a need to incorporate glycemic markers into geriatric risk stratification and to interpret their changes in the context of aging biology. Future research should focus on elucidating the mechanisms linking dysglycemia with frailty and functional decline, including the roles of sarcopenia, inflammation, and multimorbidity, and on evaluating interventions tailored to older populations across diverse global contexts.
Open AccessPrediabetes and glycemic transitions as determinants of frailty and functional decline in adults aged 50 years and older: A longitudinal analysis from five multinational aging cohorts
Background: Prediabetes is highly prevalent in older adults and is characterized by heterogeneous clinical trajectories, including regression to normoglycemia and progression to diabetes. While prediabetes has been associated with impaired physical function and frailty, the longitudinal impact of both a single diagnosis and dynamic glycemic transitions on functional outcomes remains unclear. We aimed to evaluate associations between baseline prediabetes and glycemic transitions over time with trajectories of functional capacity and frailty in older adults. Methods: We conducted a pooled analysis of harmonized data from five nationally representative longitudinal aging cohorts (MHAS, HRS, CHARLS, ELSA, CRELES) within the Gateway to Global Aging Data, including adults aged ≥50 years with ≥1 HbA1c measurements. Prediabetes was defined per ADA criteria (HbA1c 5.7-6.4%). Functional outcomes included activities of daily living (ADL), instrumental ADL (IADL), and frailty assessed using Fried phenotype, FRAIL scale, and a deficit-accumulation Frailty Index (FI). Mixed-effects Poisson models estimated incidence rate ratios (IRRs) for baseline prediabetes, while generalized estimating equations assessed time-varying glycemic status and transition trajectories. Models were adjusted for age, sex, cohort, and time-varying covariates, with sensitivity analyses including BMI, smoking, and alcohol intake. Findings: Among 18,571 participants (median follow-up 13.6 years), baseline prediabetes was associated with increased progression of functional deficits and frailty compared with normoglycemia, including higher FI values and accelerated FI progression. Prediabetes was associated with higher incidence of ADL, IADL, and multimorbidity deficits from early follow-up, although time-dependent changes in incidence rates were not significant. In time-varying analyses (n=7,840), both prediabetes and diabetes were associated with higher incidence of functional deficits compared with normoglycemia, with diabetes showing the strongest effects across all outcomes. Diabetes was associated with greater FI burden and accelerated progression, whereas prediabetes showed a smaller increase, with attenuation over time. Among individuals with baseline prediabetes, regression to normoglycemia occurred in 20.8% and was associated with increased incidence of ADL and frailty deficits. In contrast, progression to diabetes occurred in 24.3%, and was associated with lower risk of incident ADL and Fried frailty deficits compared to stable prediabetes. Interpretation: Prediabetes is associated with increased risk of functional decline, frailty, and deficit accumulation in older adults, independent of progression to diabetes. Regression to normoglycemia was associated with higher risk of functional deterioration. These findings suggest that prediabetes reflects a state of metabolic vulnerability linked to biological aging rather than solely a precursor to diabetes and highlights a need to reframe its clinical significance in older populations. Funding: This research was supported by Instituto Nacional de Geriatría in Mexico. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed up to April 1, 2026, using the terms (“prediabetes”) AND (“frailty” OR “functional decline” OR “activities of daily living” OR “mortality”) AND (“older adults” OR “aging” OR “longitudinal” OR “cohort”). Existing evidence from predominantly single-country and cross-sectional studies suggests that prediabetes is associated with increased risk of frailty, disability, and adverse health outcomes in older adults. However, findings have been inconsistent, particularly regarding incident versus prevalent outcomes and the role of competing risks in aging populations. Importantly, few studies have used harmonized multinational longitudinal data, incorporated repeated measures of glycemic status, or evaluated multiple complementary frailty constructs. The impact of dynamic glycemic transitions, including regression to normoglycemia and progression to diabetes, on functional trajectories remains poorly understood. Added value of this study: This study leverages harmonized longitudinal data from five nationally representative aging cohorts from Mexico, England, China, Costa Rica and the United States to examine both baseline prediabetes and time-varying glycemic status in relation to trajectories of functional decline and frailty. By integrating multiple validated measures of functional capacity and frailty, and applying longitudinal modeling strategies, we provide a comprehensive assessment of the relationship between prediabetes and age-related outcomes. We further characterize glycemic transition trajectories and show that regression to normoglycemia among older adults with prediabetes is associated with increased risk of frailty, while progression to diabetes does not uniformly confer additional risk beyond stable prediabetes. Implications of all the available evidence: Our results support a reconceptualization of prediabetes in older adults as a marker of systemic vulnerability rather than solely a precursor to diabetes. Glycemic status in later life appears to also reflect underlying physiological reserve, with dynamic changes potentially signaling deterioration rather than improvement. Our findings suggest a need to incorporate glycemic markers into geriatric risk stratification and to interpret their changes in the context of aging biology. Future research should focus on elucidating the mechanisms linking dysglycemia with frailty and functional decline, including the roles of sarcopenia, inflammation, and multimorbidity, and on evaluating interventions tailored to older populations across diverse global contexts.
- Open Access
- 22 April 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 59, 101477
Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City
- 22 April 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 59, 101477
Open AccessAssessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City
- Open Access
Predictive performance of seven clinical surrogates of visceral adipose tissue for cardiovascular mortality: A sub-analysis of 102,385 adults from the Mexico City Prospective Study
BACKGROUND: Visceral adipose tissue (VAT) has been associated with cardiovascular disease (CVD) mortality. However, the comparative performance of VAT-related clinical surrogates remains poorly characterized. OBJECTIVES: To evaluate the performance of seven VAT-related clinical surrogates for predicting CVD and cause-specific CVD mortality. METHODS: We analyzed data from the Mexico City Prospective Cohort, a population-based prospective cohort study, with baseline recruitmetn between 1998 – 2004 and ongoing mortality follow-up. CVD mortality included deaths from cardiac, stroke-related, and other vascular causes. Seven VAT-related surrogates (METS-VF, CVAI, EVA, DAAT, LAAP, VAI, and DAI) were estimated using clinical, biochemical, and anthropometric data at baseline. Associations with outcomes were evaluated using Cox regression models to estimate adjusted hazard ratios (aHRs). Discrimination was assessed with Harrell’s C-statistic (Cs) and fixed-point at 10-years receiver operating characteristic (ROC) curves, and calibration with slope plots. RESULTS: In a subsample of 102,385 participants (median age: 47 years; 67% female), 4,068 (3.97%) died from any CVD causes. METS-VF (Cs: 0.722; aHR: 1.17, 95% CI: 1.12–1.23), EVA (Cs: 0.72; 1.14, 1.12–1.23), CVAI (Cs: 0.70; 1.13, 1.09–1.18), and DAAT (Cs: 0.626; 1.13, 1.09– 1.18) were positively associated with CVD mortality and showed the highest predictive capacity among the surrogates. Adding METS-VF to a CVD risk score among individuals classified as intermediate risk improved discrimination for CVD mortality. CONCLUSIONS: In this large cohort of Mexican adults, four VAT-related clinical surrogates, particularly METS-VF, demonstrated good discriminatory performance for long-term CVD mortality. These indices could help to identify individuals with high VAT accumulation and high CVD risk in resource-limited settings.
Open AccessPredictive performance of seven clinical surrogates of visceral adipose tissue for cardiovascular mortality: A sub-analysis of 102,385 adults from the Mexico City Prospective Study
BACKGROUND: Visceral adipose tissue (VAT) has been associated with cardiovascular disease (CVD) mortality. However, the comparative performance of VAT-related clinical surrogates remains poorly characterized. OBJECTIVES: To evaluate the performance of seven VAT-related clinical surrogates for predicting CVD and cause-specific CVD mortality. METHODS: We analyzed data from the Mexico City Prospective Cohort, a population-based prospective cohort study, with baseline recruitmetn between 1998 – 2004 and ongoing mortality follow-up. CVD mortality included deaths from cardiac, stroke-related, and other vascular causes. Seven VAT-related surrogates (METS-VF, CVAI, EVA, DAAT, LAAP, VAI, and DAI) were estimated using clinical, biochemical, and anthropometric data at baseline. Associations with outcomes were evaluated using Cox regression models to estimate adjusted hazard ratios (aHRs). Discrimination was assessed with Harrell’s C-statistic (Cs) and fixed-point at 10-years receiver operating characteristic (ROC) curves, and calibration with slope plots. RESULTS: In a subsample of 102,385 participants (median age: 47 years; 67% female), 4,068 (3.97%) died from any CVD causes. METS-VF (Cs: 0.722; aHR: 1.17, 95% CI: 1.12–1.23), EVA (Cs: 0.72; 1.14, 1.12–1.23), CVAI (Cs: 0.70; 1.13, 1.09–1.18), and DAAT (Cs: 0.626; 1.13, 1.09– 1.18) were positively associated with CVD mortality and showed the highest predictive capacity among the surrogates. Adding METS-VF to a CVD risk score among individuals classified as intermediate risk improved discrimination for CVD mortality. CONCLUSIONS: In this large cohort of Mexican adults, four VAT-related clinical surrogates, particularly METS-VF, demonstrated good discriminatory performance for long-term CVD mortality. These indices could help to identify individuals with high VAT accumulation and high CVD risk in resource-limited settings.
- Open Access
- 16 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 56, 101403
External validation and recalibration of cardiovascular risk scores for prediction of 10-year risk of fatal cardiovascular disease: a prospective, observational, population-based cohort analysis of adults in Mexico City
- 16 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 56, 101403
Open AccessExternal validation and recalibration of cardiovascular risk scores for prediction of 10-year risk of fatal cardiovascular disease: a prospective, observational, population-based cohort analysis of adults in Mexico City